INTRODUCTION
Male breast cancer is a rare condition, comprising only approximately 1% of all breast malignancies. 1 Given its rarity, it has been difficult to study, and its etiology remains elusive. Genetic risk factors, including relations with familial history and BRCA gene mutations, 2 are well established, but other environmental risk factors are less clear.
Female breast cancer is well recognized as being influenced by hormonal factors. 3 It seems the same is true for male breast cancer, given that studies have identified high risks related to obesity, 4 -10 physical inactivity, 4, 9, 10 exogenous hormone use, 11-14 and diabetes. 7, 15 Investigations have also reported high risks among patients with Klinefelter syndrome (condition characterized by 46-XXY karyotype and relative excesses of estrogens in relation to androgens) [16] [17] [18] as well as gynecomastia (enlargement of male mammary glands often associated with hormonal perturbations). 8 Collectively, these findings emphasize the need for assessing the roles of endogenous hormones in relation to male breast cancers. High levels of both estrogens and androgens have been implicated in female breast cancer, 19 ,20 but studies have not yet been conducted to assess their roles in the etiology of male breast cancer.
We recently reported results regarding hormonerelated risk factors from the Male Breast Cancer Pooling Project, a consortium of 21 case-control and cohort investigations. 5 From seven of the contributing cohort studies, we were able to access prediagnostic serum or plasma samples, from which hormones could be measured. We report herein the results of this analysis, in which we were able to assess male breast cancer risk in relation to various estrogens and androgens and their ratios.
PATIENTS AND METHODS

Study Population
Male breast cancer cases and matched controls were derived from seven cohorts (Fig 1) that had been part of the Male Breast Cancer Pooling Project and could contribute prediagnostic serum or plasma samples. [21] [22] [23] [24] [25] [26] [27] These studies contributed deidentified data and biologic materials after institutional review board and data-sharing agreement approvals. Breast cancer cases were required to be incident (ie, diagnosed after exposure assessment) but did not have to be the first diagnosed cancer. Risk factor information was available primarily from completed questionnaires, although in one study, 23 such data were obtained via linkage with population registries.
We asked each study to provide 40 controls per case matched on sex, race, year of birth (Ϯ 1 year), year of cohort entry (Ϯ 1 year), and exit date (diagnosis of cancer [excluding nonmelanoma skin cancer], death, loss to follow-up, or end of follow-up Ն date of diagnosis of index case). 5 If the index case had Ն 0.7 mL serum/plasma available for hormone quantitation, we requested that two of the 40 controls be selected using the following additional criteria: Ն 0.7 mL serum/plasma available, year of blood draw (Ϯ 1 year), and number of freeze/thaw cycles. We were unable to identify a complete set of controls for all matched sets, and one study 21 attempted to match three controls per case; thus, in total, there were 101 breast cancer cases and 217 controls. Androstenedione   3  T  H  D  e  n  o  r  e  t  s  o  t  s  e  T  e  n  o  r  t  s 
Schematic of sex steroid hormone metabolism. Sex steroid hormones that were quantitated are underlined. (*) Note that only nine are underlined, but 11 assays were conducted; this is because 3-androstanediol glucuronide (3␣-diol-G) was quantitated as separate metabolites of 3-androstanediol-3 glucuronide and 3-androstanediol-17 glucuronide. ADT, androsterone; ADT-G, androsterone glucuronide; DHEA, dehydroepiandrosterone; DHT, dihydrotestosterone.
Laboratory Analysis
In collaboration with the Pharmacogenomics Laboratory of Laval University, Québec City, Québec, Canada, we quantitatively assessed the following unconjugated sex steroid hormones by gas chromatography-mass spectrometry: dehydroepiandrosterone, androstenediol, androstenedione, testosterone, dihydrotestosterone (DHT), androsterone, estrone (E1), and estradiol (E2). Using liquid chromatography-tandem mass spectrometry, we measured glucuronide derivatives of androgens, namely 3-androstanediol-3 glucuronide (3␣-diol-3G), 3-androstanediol-17 glucuronide (3␣-diol-17G), and androsterone glucuronide (ADT-G). No sulfates are reported. These hormones cover a wide array and key positions of the sex steroid biosynthesis pathway, including both androgens and estrogens (Fig 2) . Cases, their matched controls, and blinded quality control (QC) samples from each cohort were randomly assigned throughout the batches with matched sets assayed in the same batch. At the time of random assignment, an additional four blinded QC samples from the same two individuals were added to each batch. Results from these QC samples were used to assess the assays across the entire study. Except for 3␣-diol-17G, overall coefficients of variance (CVs) ranged from 2.5% to 12.3%; for 3␣-diol-17G, the overall CV was 43.5% because of one outlier observation. With this removed, the CV for 3␣-diol-17G was 5.0%.
Statistical Analysis
To assess associations between each hormone and male breast cancer, we used logistic regression models to estimate covariate-adjusted odds ratios (ORs) and 95% CIs. Before these logistic regression analyses, we adjusted all hormones to reduce the influence of study-related variability. 28 Using all participants with baseline (prediagnostic) quantitation, we regressed each log-transformed hormone on study and age. Study betas were summed and divided by the number of studies minus one. This value was subtracted from each of the study betas to generate study-specific correction factors, which were subtracted from the log-hormone concentrations to generate individuallevel, study-corrected log hormone concentrations.
Each exposure was assessed after being categorized into quartiles using cut points based on the exposure distribution of all participants with baseline hormone quantitation, as well as assessed as a continuous metric with standardization to half the value of the interquartile range, such that continuous estimates of association were approximately per-quartile increase in exposure. 29 In addition to assessing individual exposures, we also assessed combinations and ratios of hormones that were metabolically close. These a priori-specified exposures included: E2 to testosterone ratio; testosterone to DHT ratio; E1 to androstenedione ratio; E2 to E1 ratio; parent estrogens (E1 plus E2); E2 to sum of ADT-G, 3␣-diol-3G, 3␣-diol-17G, and DHT ratio; and parent estrogens (E1 plus E2) to sum of ADT-G, 3␣-diol-3G, 3␣-diol-17G, and DHT ratio.
We performed both conditional and unconditional analyses of the data. Conditional models using original or study-adjusted hormone values, and unconditional models using original hormone values with model adjustment for study, did not materially alter the results. Therefore, we present results from the unconditional analyses using the study-adjusted hormone values. In these analyses, we adjusted for race, date of blood draw (continuous calendar years), and age at blood draw (continuous years). Modeling dates or ages as categorical, instead of continuous, variables had minimal effects on risk. We also assessed whether adjustment for study, body mass index (BMI), family history of breast cancer, diabetes, cigarette smoking (ever v never, currency, pack-years, duration, and intensity), and alcohol consumption (currency and grams consumed per day) changed OR estimates by Ͼ 10%. None of these covariates consistently altered the estimates obtained, but we included BMI as a continuous variable in the fully adjusted model, given previous evidence that this is associated with both male breast cancer risk and hormone levels and because adjustment resulted in slight modifications of risk. Because we did not have information on Klinefelter syndrome or gynecomastia from any studies, we could not measure potential confounding effects. We assessed whether relations between hormones and male breast cancer were modified by several risk factors by performing likelihood ratio tests of nested models with and without a hormone-risk factor interaction term. Heterogeneity was assessed in the same way using a hormone-study interaction term. All tests were two sided, and P values Ͻ .05 were considered statistically significant. Analyses were conducted using STATA software (version 13; STATA, College Station, TX).
RESULTS
Among the 101 male breast cancer cases and 217 controls, the average age at blood draw was 51.6 and 50.9 years, respectively ( Table 1 ). The mean age at diagnosis among cases was 66.9 years.
A family history of breast cancer in a first-degree relative was more common among the cases than the controls, whereas there were no major differences with respect to mean BMI or history of diabetes. Cases were significantly less likely than controls to report a history of cigarette smoking but somewhat more likely to report having consumed alcohol. Quantitation of the primary sex steroid hormones revealed levels that would be expected from a middle-age male population using mass spectrometry technologies.
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Among the controls, androgen levels declined significantly with age at blood draw, whereas estrogen levels increased (Appendix Table  A1 , online only). In addition, BMI affected many of the hormones, with higher BMI associated with lower androgen and somewhat higher E2 levels. Substantial and significant correlations were found between E2 and E1 (r ϭ 0.74), testosterone and DHT (r ϭ 0.74), testosterone and androstenediol (r ϭ 0.54), testosterone and androstenedione (r ϭ 0.53), and androstenedione and androstenediol (r ϭ 0.47). E2 was significantly correlated with testosterone (r ϭ 0.50), but correlations between other androgens and estrogens were weaker, and many were not statistically significant. Hormone concentrations among controls were similar across studies (Appendix Table A2 , online only). Table 2 summarizes risks associated with hormone analytes after adjustment for race, date at blood draw, and age at blood draw-and then in addition for BMI. Although there were not major differences in the two sets of ORs, we chose to focus on the more fully adjusted estimates, which in some instances were based on slightly reduced numbers, given missing information on BMI. In general, androgens were unrelated to risk, although there was a slightly increased risk associated with elevated testosterone levels (OR Q4 v Q1 , 1.53; 95% CI, 0.73 to 3.17; trend P ϭ .59). This relation, however, was much less impressive than those seen for estradiol, where those in the highest quartile had an OR of 2.47 (95% CI, 1.10 to 5.58) compared with those in the lowest quartile (trend P ϭ .06). Estrone was not significantly related to risk (OR Q4 v Q1 , 1.32; 95% CI, 0.63 to 2.79; trend P ϭ .60).
Further assessment of estrogens as a ratio to various individual androgens or sum of androgens showed no additional discrimination of risk beyond that seen with the estrogens or androgens alone (Table 3) . We observed elevated, but not statistically significant, risks for high levels of the ratio of E2 to testosterone (OR Q4 v Q1 , 1.95; 95% CI, 0.90 to 4.24; trend P ϭ .14). We also observed a positive relation for the ratio of E2 to the sum of androgens downstream in the metabolic pathway from testosterone (ie, sum of ADT-G, 3␣-diol-3G, 3␣-diol-17G, and DHT), with the highest quartile providing an OR of 2.27 (95% CI, 0.98 to 5.29; trend P ϭ .34). Although those with high summed E1 plus E2 showed some risk elevation (OR Q4 v Q1 , 1.57; 95% CI, 0.70 to 3.53; trend P ϭ .27), there was no further distinction in risk when this measure was examined as a ratio to testosterone levels or sum of androgens.
We assessed whether there was heterogeneity in hormone relations according to various identified risk factors (Table 4) . We saw somewhat stronger associations for most hormones among younger (age Ͻ 67 years) compared with older men (eg, highest v lowest quartile for E2: OR, 3.17; 95% CI, 1.06 to 9.42 v OR, 1.70; 95% CI, 0.49 to 5.91), but the difference was not statistically significant (heterogeneity P ϭ .68). No substantial or consistent differences in hormone relations were observed according to other potential risk factors, including BMI (Table 4) or dichotomized exposures of cigarette smoking or alcohol consumption (data not shown).
We also assessed whether hormone associations differed according to whether tumors were diagnosed within or after 10 years of blood draw, but these analyses revealed no distinctive differences (Appendix Table A3 , online only). Analyses that specifically excluded cases diagnosed within the first 3 years after blood draw also showed no major risk differences (data not shown).
DISCUSSION
In this apparent first-time assessment, we found that male breast cancer risk was influenced by prediagnostic endogenous estradiol. Circulating androgen levels did not seem to be associated with much risk alteration; thus, when we examined estradiol in relation to androgens, there was no additional enhancement of risk beyond that already seen with estradiol levels.
In observing a relation of male breast cancer with high estradiol levels, results are consistent with those for postmenopausal female Abbreviations: 3␣-diol-3G, 3-androstanediol-3 glucuronide; 3␣-diol-17G, 3-androstanediol-17 glucuronide; ADT-G, androsterone glucuronide; DHT, dihydrotestosterone; OR, odds ratio.
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Adjusted for race, date at blood draw, and age at blood draw. Continuous sex steroid hormone values were standardized to half of difference between 75th and 25th centiles of distribution before correlative analysis.
†Adjusted additionally for body mass index as continuous variable.
breast cancer. 19, 20, [33] [34] [35] [36] Interestingly, the magnitude of risk associated with high levels of estrogens is similar for female and male breast cancers, being on the order of two-to three-fold for the highest versus lowest quartiles of estradiol levels. Although estrogen-mediated carcinogenesis is not well understood, potential mechanisms include mutagenic action and stimulation of cell proliferation, which may increase risk of neoplastic transformation and/or neoplastic progression.
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Although the etiologic role of androgens in male breast cancer is unclear, studies in women support associations independent of estrogens.
19,20,36 Androgens may increase breast cancer risk directly by increasing cell growth and proliferation or indirectly by peripheral conversions to estrogens within a number of tissues, including adipose and breast tissues. 39 Although androgens are a likely relevant physiologic mechanism with respect to the development of estrogen receptor (ER) -responsive tumors, we did not have complete information on either ERs or androgen receptors for the tumors studied and thus could not differentiate risks according to tumor subtype. On the basis of other studies, 40 we can assume that most of the male breast cancers we studied would have been ER positive and probably androgen receptor positive. Although it would have been of interest to examine hormone relations according to hormone receptor status of the tumors, it is noteworthy that some recent studies of female breast cancer have found hormone relationships to prevail for both hormone receptor-positive and -negative tumors, 41 suggesting that hormones may act through molecular pathways that do not directly involve the receptors found within the tumor itself.
The incidence of male breast cancer is approximately 100ϫ lower than that of female breast cancer, which likely reflects sex differences in breast cancer pathogenesis, including the numbers and types of cells available for carcinogenic transformation. 42 Gynecomastia is a recognized risk factor for male breast cancer, and it is believed to develop mainly because of a disequilibrium between free estrogen and androgen in breast tissue. 43 We had no information on the development of gynecomastia and thus could not determine whether the effects of estrogens on male breast cancer were mediated through more tissue at risk. However, data from the case-control studies that contributed data to this pooling project 5 and that collected information on gynecomastia indicated that it was a fairly rare event. This would support that high levels of estrogens could be a biomarker of risk even in the absence of diagnosed gynecomastia.
It has been proposed that male breast cancer may arise as a result of a high ratio of estrogens to androgens. 44 This speculation derives mainly from findings that patients with Klinefelter syndrome are at an elevated risk of male breast cancer. Such patients, during adolescence, begin to exhibit elevated levels of gonadotropins and decreased levels of testosterone, resulting in their characteristic body proportions and gynecomastia. 17 In adults, low testosterone levels are a cardinal feature of Klinefelter syndrome, 45 along with high estradiol levels from overexpression of aromatase CYP19. 46 However, our results only infer that the ratio of estradiol to testosterone and the sum of various androgens may be associated with male breast cancer; none of these analyses were statistically significant at P Ͻ .05. In postmenopausal female breast cancer, there is a high correlation between BMI and estrogen levels, specifically free estradiol levels. 47 Although estradiol seems to remain a significant risk factor after adjustment for BMI, the reverse is apparently not true; the association of BMI with postmenopausal breast cancer in two studies entirely disappeared after adjustment for free estradiol levels. 48, 49 In addition, there is evidence in female breast cancer that exogenous estrogens [50] [51] [52] have stronger effects on relative risks in thin women (eg, BMI Ͻ 25 kg/m 2 ), supporting that obese women have high estrogen levels that prevent additional effects of other hormones.
These findings in women therefore stimulated our interest in evaluating confounding and effect modifications of hormone levels by BMI in men. However, we did not find that there were large differences in hormone relations after adjustment for BMI, nor did we find that hormone relations varied substantially by BMI level. This may reflect that hormones are not as strongly influenced by BMI in men compared with women, although we did find some evidence of variations of hormone levels by BMI, particularly androgens, which were inversely correlated, as has been noted by others.
53-55 However, we could not specifically assess relations with free testosterone, given that we did not measure sex hormone-binding globulin (SHBG). Free testosterone may be more influenced by BMI than total testosterone, because as SHBG levels decrease, the levels of free testosterone increase, requiring less total testosterone to maintain the feedback loop. A similar relation with BMI has been seen among women with respect to free versus total estradiol levels. 48 Our results did suggest some possible effect modification of hormones by age at development of breast cancer, with estradiol being more strongly related to younger-than older-onset cancers. Although female breast cancer is recognized as showing distinctive clinical and risk factor differences by age at diagnosis, 56 much less is known regarding these parameters for male breast cancer. One large series recently reported that younger patients with male breast cancer had types of tumors that are generally associated with a poor prognosis in women, including ER-and/or progesterone receptor-negative tumors and human epidermal growth receptor 2-positive tumors. 40 It is, however, unclear whether these or other tumor characteristics would be influenced by endogenous hormones.
This study had a number of strengths but some limitations as well. Although this is the only prospective study to our knowledge to assess endogenous hormones in relation to male breast cancer risk, the number of cases for analysis was modest, reflecting the general rarity of this disease. Samples were collected before diagnosis, oftentimes many years and at varying times before diagnosis. We had no information on SHBG, and although we had information on various risk factors, we did not have access to some parameters that would have been of interest, including BRCA status, gynecomastia, and Klinefelter syndrome. Finally, we lacked information on clinical parameters, including hormone receptors.
In conclusion, in this investigation to assess the role of endogenous hormones in the etiology of male breast cancer, we found, as in postmenopausal female breast cancer, a strong relation with estradiol levels. Androgens were much less important predictors, and as a result, the ratio of estrogens to androgens was not as important as has been previously speculated. Future studies may benefit from a focus on the mediating effects of estrogens on breast cancer among men with gynecomastia and/or Klinefelter syndrome.
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